Skip to main content
Premium Trial:

Request an Annual Quote

Good Start Genetics EmbryVu

Good Start Genetics has launched EmbryVu, a preimplantation genetic screening test. The process begins with the safe removal of a few cells from embryos created during the in vitro fertilization process. EmbryVu tests for the presence or absence of whole chromosomes in each sample to determine those with the expected number. Embryos found to have more or fewer chromosomes than expected are referred to as aneuploid, and can fail to implant or result in miscarriage. Because EmbryVu will help fertility specialists select embryos for transfer that have a normal chromosome complement, it is expected to significantly increase the chances of a successful pregnancy. EmbryVu is based on FAST-SeqS (Fast Aneuploidy Screening Test-Sequencing System) technology exclusively licensed from Johns Hopkins University. For more on Good Start's test, click here.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.